Switch to PDF viewer

Back to Collection

Pharmafile - Summer 2022

Welcome to issue 73 of Pharmafile! This edition covers topics including respiratory research, oncology, and pain management

Chelsea Harbour Hotel

Chelsea Harbour Hotel: PharmaTimes Awards

Contents

This edition covers topics such as oncology, respiratory diseases, pain management and rare diseases

Foreword: A technological revolution that works for all

Paul O'Donohoe explores the changing landscape of the healthcare industry and the gradual transformation to a more digital world

PMGGROUP

PMGroup Webinars

Novel targets are the future of solid tumour immunotherapy

Pharmafile speaks to Enara Bio: Enara Bio tell Pharmafile about the unmet patient needs in oncology, and how these can be tackled by novel therapies, as well as considering the future of immunotherapy

QIC Dermatology

QIC Dermatology: Quality in Care Programme

New treatments and new challenges: The oncology constant is change

The UK has seen many innovations in the healthcare sphere, many have which have been in oncology, but what are the next steps in this ever-evolving field?

Embrace disruption: the changing landscape of clinical research

How can precision medicine and personalised treatments improve healthcare in Europe and worldwide?

A targeted approach to developing targeted blood cancer therapies

Precision medicine and targetted solutions can be utilised to treat cancer, but how can this develop in the future?

Supporting the challenges of innovative systemic treatments

How can the benefits of immunotherapy be maximised for each patient?

NHS waiting lists: the second healthcare crisis?

Novartis UK tells Pharmafile how COVID-19 impacted patient access to oncology treatments, and how the pharma industry can support the NHS

Helping the world prepare for future pandemics

Pharmafile speaks to Open Orphan: Open Orphan tells Pharmafile about the respiratory disease landscape, as well as how human challenge trials may further understanding of the area

Dose and deliver: How PMDIs are transforming asthma and COPD treatments

Aptar Pharma discuss how PMDIs continue to change the landscape of asthma and COPD treatment

Aptar Pharma

Aptar Pharma: Working daily to improve the health of our patients and our planet

Improving outcomes in idiopathic pulmonary fibrosis

Galecto tells Pharmafile about the benefits of inhaled technology to treat idiopathic pulmonary fibrosis

ROCK2 the top: the future of IPF therapeutics

RedX share their thoughts about the current and future treatments for idiopathic pulmonary fibrosis

PharmaTimes

Pharmatimes: Clinical Researcher of the Year - The Americas!

Medical cannabis - The inhaled answer to cancer and non-cancer pain?

Pharmafile speaks to Sapphire Clinics: Sapphire Clinics discuss the benefits of medical cannabis for pain management and how this has changed in the last decade